- Home
- IBRX vs RKT Comparison
IBRX vs RKT Comparison
Compare IBRX & RKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- RKT
- Stock Information
- Founded
- IBRX 2014
- RKT 1985
- Country
- IBRX United States
- RKT United States
- Employees
- IBRX N/A
- RKT N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- RKT Finance: Consumer Services
- Sector
- IBRX Health Care
- RKT Finance
- Exchange
- IBRX Nasdaq
- RKT Nasdaq
- Market Cap
- IBRX 1.9B
- RKT 1.9B
- IPO Year
- IBRX N/A
- RKT 2020
- Fundamental
- Price
- IBRX $3.42
- RKT $13.25
- Analyst Decision
- IBRX Strong Buy
- RKT Sell
- Analyst Count
- IBRX 3
- RKT 13
- Target Price
- IBRX $13.58
- RKT $13.81
- AVG Volume (30 Days)
- IBRX 6.0M
- RKT 3.2M
- Earning Date
- IBRX 03-18-2025
- RKT 02-27-2025
- Dividend Yield
- IBRX N/A
- RKT N/A
- EPS Growth
- IBRX N/A
- RKT N/A
- EPS
- IBRX N/A
- RKT N/A
- Revenue
- IBRX $7,332,000.00
- RKT $4,304,653,000.00
- Revenue This Year
- IBRX $2,359.81
- RKT $13.36
- Revenue Next Year
- IBRX $808.10
- RKT $31.76
- P/E Ratio
- IBRX N/A
- RKT N/A
- Revenue Growth
- IBRX 1218.71
- RKT 13.77
- 52 Week Low
- IBRX $2.28
- RKT $10.06
- 52 Week High
- IBRX $10.53
- RKT $21.38
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- RKT 58.16
- Support Level
- IBRX $3.35
- RKT $12.60
- Resistance Level
- IBRX $4.27
- RKT $13.45
- Average True Range (ATR)
- IBRX 0.31
- RKT 0.51
- MACD
- IBRX 0.04
- RKT 0.04
- Stochastic Oscillator
- IBRX 29.17
- RKT 86.03
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About RKT Rocket Companies Inc.
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and is now the largest mortgage originator in the U.S. as well as the servicer for more than 2 million loans.